Nine new vanadium complexes, with tridentate Schiff base ligand based on 3,5-di-tert-butyl--2-hydroxybenzaldehyde and different hydrazides, are described and characterized. The X-ray crystal structure of complex 8 shows distorted octahedral geometry of vanadium, with ONO ligand in equatorial position. The tridentate Schiff base ligand forms six membered and five--membered chelate rings at the V(V) acceptor center, with the corresponding bite angles being 82.97(9)˚ and 74.48(9)˚. The molecules are gathered by means of intermolecular O-HN hydrogen bond and layered by ππ interactions involving the pyridine and phenolate rings. Such interactions expand the structure along the crystallographic a axis. The complexes were characterized by the elemental analyses, IR, UV-Vis, EPR spectroscopy, cyclic voltammetry, thermogravimetry and magnetic susceptibility measurements. The stabilization role of co-ligands is discussed. The cytotoxicity versus HepG2 hepatocytes and inhibition of human recombinant PTP1B was studied.
Introduction
Schiff bases are an important class of ligands both in the medicinal and pharmaceutical fields. The coordination to vanadium spread the applications to such a biological activity as antibacterial, anti-inflammatory, antiviral, antifungal, anticancer and antipyretic properties [1] [2] [3] [4] [5] [6] [7] . One of the significant role of vanadium was found recently as decreasing the resistance to oncolytic immunotherapy [8] . On the other hand, chemistry and properties of vanadium complexes with Schiff bases allowed us to study the possible coordination modes of vanadium, stability of its oxidation states, role of co-ligands and the stability in solution [9, 10] .
It has been also shown that vanadium compounds are potent inhibitors of phosphatases, especially protein tyrosine phosphatases such as PTP1B, TCPTP, PTP-MEG2, SHP-1, SHP-2, LAR [11] [12] [13] . This leads to the modulation of various cellular functions and may be the basis for the therapeutic use of vanadium compounds in metabolic, neoplastic, inflammatory, neurodegenerative and other diseases. The beneficial effects of vanadium compounds have been observed in studies using cells (including cancer) and in animal studies demonstrating the potential therapeutic efficacy of this group of phosphatase inhibitors.
Adverse and toxic effects of vanadium compounds have been observed in numerous preclinical, animal models during studies of pharmacological activity of vanadium compounds, mainly in antidiabetic and antitumor activity tests [14] . Numerous side and toxic effects of vanadium compounds affect most of the systems and organs of the body. This includes the respiratory, digestive and cardiovascular system as well as blood, brain, liver and kidneys. Vanadium also exhibit reproductive toxicity, influence on developmental processes and have potential to exert teratogenic and carcinogenic activity [15] [16] [17] . Several studies on preclinical animal models have provided strong evidence that the toxicity of vanadium compounds is related to several factors including species, dose, route and duration of administration as well as to the nature of the compound [18, 19] . Organic vanadium compounds were recognised as much safer than inorganic vanadium salts [20] and antidiabetic potency and efficacy as well as toxicity may be modified by reasonable ligand binding of vanadyl ions [21] . The possibility of modulating the biological effects of vanadium (minimizing toxic effects and preserving the pharmacological activity) by modification the structure of organic ligands has been demonstrated by number of studies [22] [23] [24] . 6 (0.1 M) as the supporting electrolyte, using Pt working and counter and Ag/AgCl as reference electrodes on an AU-TOLAB/PGSTAT 128 N Potentiostat/Galvanostat. E 1/2 values were calculated from the average anodic and cathodic peak potentials, E 1/2 = 0.5(E a + E c ). The redox potentials were calibrated versus ferrocene (0.440 V versus SHE), which was used as an internal potential standard for measurements in organic solvents to avoid the influence of a liquid junction potential; the final values are reported versus the standard hydrogen electrode (SHE). Assessment of pharmacological activity included in vitro evaluation of PTP1B inhibition by an enzyme-based assay [26] .
Tridentate hydrazido-hydrazones vanadium complexes. Synthesis, properties and biological activity
For determination the ability of tested compounds to inhibition of human recombinant PTP1B previously described method was used [26] . To the solution of the tested compounds on black 384-well microplate wells (PerkinElmer) an equal volume of a test solution of phosphatase 50 ng mL−1 PTP1B (1.5 U ml-1) was added in a reaction buffer: 25 mM of 3-(N-morpholino)propanesulfonic acid (MOPS), 50 mM NaCl, 1 mM dithiothreitol (DTT) and 0.05% Tween-20, pH 7.0. After 10 minutes, a solution of phosphate 6,8-difluoro-4-methyl (DiFMUP) was added until its final concentration was 0.1 mM. After 20 minutes of incubation at room temperature, the fluorescence intensity (excitation 355 and emission 560 nm) was measured on a multifunctional plate reader POLARstar Omega (BMG Labtech, Germany).
Cytotoxicity assay was performed using PrestoBlue Cell Viability Reagent (ThermoFisher Scientific), a cell permeable resazurin-based reagent that functions as a cell viability indicator by using the reducing power of living cells (mitochondrial enzymes activity) to quantitatively measure the proliferation of cells. Human hepatocytes HepG2 seeded 18-24 hours before experiments in 96-well microplate (1x103 in 100 µl DMEM with 10% FBS) were incubated with tested compounds at 37°C and 5% CO 2 . After 24 hours incubation, 10 μl of PrestoBlue reagent was added to each microplate well and microplate was mixed on orbital shaker. Plates were incubated for 20 minutes and the fluorescence intensity at 560 nm excitation and 590 nm emission was determined using multi-mode microplate reader POLARstar Omega (BMG Labtech, Germany). The results were normalized to the control (cells with solvent only), wherein the intensity of fluorescence was taken as 100%.
Statistical analysis was performed by analysis of variance followed by the Tukey test for post hoc comparisons using GraphPad Prism 6.0 software (GraphPad Software, USA).
Synthesis
In Table 1 the ligand notation is shown. 
[{VO(L 2 )(EtO)}{V(L 2 )(EtO) 2 }(µ-O)], 2
The complex was synthesized by us in 2010 by different method than that described in the literature [27] . The synthesis of the complex was under patent procedure and we could not published the results before 2017. The bald (0.352 g, 1.5 mmol), 2-hydroxybenzhydrazide (0.228 g, 1.5 mmol) and EtOH (30 ml) were refluxed for 15 minutes (yellow solution was observed). Then VOSO 4 aq (0.333 g, 1.5 mmol) was added and mixture was refluxed for additional 90 minutes. The solution turned to dark yellow-brown and formation of yellow-brown precipitation was observed. The crystals were filtered off, washed with cold EtOH and dried in air. Yield: 0. 
[VO(L 5 )(EtO)], 6
The bald (0.352 g, 1.5 mmol) and the 3-hydroxy-2-naphthoic acid hydrazide (0.303 g, 1.5 mmol) were dissolved in 80 ml of EtOH under Ar flow on a magnetic stirrer. The mixture was refluxed for 35 minutes with constant stirring and the temperature was raised to 100 o C. Then VOSO 4 aq (0.333 g, 1.5 mmol) and 15 ml of EtOH were added and the mixture was refluxed for 180 minutes. After that, the volume of the reaction mixture was concentrated to final volume of ca. 20 ml and cooled to the room temperature. 
[VO(L 2 )(maltol)], 10 and [VO(L 3 )(bpy)]·MeOH, 11
The syntheses and physicochemical characterization of the 10 and 11 complexes were described and discussed in [28] . In this paper we present the pharmacological activity of these compounds.
Crystallographic data collection and structure refinement
Crystal data, data collection and structure refinement details are summarized in Table 2 . Positions of all of non-hydrogen atoms were determined by direct methods using SHELXT2017 [29] . All non-hydrogen atoms were refined anisotropically using weighted full-matrix least-squares on F 2 . Refinement and further calculations were carried out using SHELXL2017 [30] . All hydrogen atoms joined to carbon atoms were positioned with an idealized geometries and refined using a riding model with U iso (H) fixed at 1.5 U eq of C for methyl groups and 1.2 U eq of C for other groups.
Results and Discussion
The Schiff base formed in situ in EtOH solution reacts with the appropriate vanadium substrate, yielding the complexes 1-9. We used two different V(IV) sources -[VO(acac) 2 ] or VOSO 4 aq and it was found that the product formula does not depend on substrate, as shown in synthesis of 7. But in some cases, the solubility of VOSO 4 is low in EtOH, resulting in formation of undissolved substrate, which can contaminates the product. Thus the time of reflux had to be carefully controlled. As the ligand L n (n = 1-6) is tridentate, the complex needs a co-ligand to fill the coordination sphere. When additional co-ligand is not added, vanadium coordinates or solvent molecule (as in case of 2, 6-8) or ligand L n (complex 3) or its components (complex 4). The coordination of solvent molecule results in redox instability of the product and the oxidation to V(V) in most cases is observed (complexes 2, 6, 8) . Also maltol as co-ligand does not stabilize the +4 oxidation state (complex 1). When phen was used (complexes 5 and 9), the complexes are fairly stable in air and can be kept in air for long period (within 9 years after preparation only a small decrease in magnetic moment is observed).
Crystal structure
A single crystal X-ray study reveals that the asymmetric part of the unit cell of the complex, [VO(L 6 )(EtO)(EtOH)] (8) ) and one ethanol molecule. The asymmetric unit of the complex with the adopted atomic numbering scheme is shown in Fig. 1 . The crystallographic data and detailed information on the structure solution and refinement for 8 are given in Table 2 . Selected bond distances and bond angles are listed in Table 3 . (2) C7-N9 1.300 (4) C7-O8 1.302 (4) N9-N10 1.399 (3) N10-C11 1.285 (4) O33-V1-O27 103.20 (12) O33-V1-O18 97.89 (11) O27-V1-O18 101.32 (9) O33-V1-O8 100.02 (11) O27-V1-O8 95.38 (10) O18-V1-O8 151.97 (10) O33-V1-N10 93.85 (11) O27-V1-N10 161.56 (11) O18-V1-N10 82.97 (9) O8-V1-N10 74.49 (9) O33-V1-O30 171.31 (11) O27-V1-O30 85.40 (10) O18-V1-O30 78.93 (9) O8-V1-O30 80.16 (9) N10-V1-O30 77.78 (9) In the structure surroundings of the central V V form a distort- than the other groups, and for the complex the V-O oxo distance is equal to 1.589(2) Å, which is in agreement with data for other pentacoordinate oxovanadium(V) compounds [32] [33] [34] . In the complex the four V-O bond lengths are unequal, with the V=O bond being the shortest and the V-O30 = 2.336(2) Å (enolate) bond the longest. The magnitude, 2.113(2) Å, of the V1-N10 bond indicates a low affinity between the imine N atom and the central atom in neutral oxidovanadium(V) complexes. The V-O bond lengths follow the order: V-O33oxo > V-O27ethoxo > VO18phenoxo > V-O8alkoxo > O30enolate. These data indicate stronger binding of the alkoxo group compared to the enolate oxygen atoms. Analysis of the crystal structure of 8 at the supramolecular level reveals that the complex molecules are held together by typical hydrogen and two π⋅⋅⋅π interactions (Fig. 2) , which are summarized in Tables 4 and 5 , respectively. All these interactions are responsible for the self-assembly of the complex molecules and stabilization of the 3D structure. Table 4 . Hydrogen-bond geometry (Å, °)
Crystal data
O30-H30⋅⋅⋅N4 
UV-Vis spectra
The UV-Vis spectral data are collected in Synthesis for each complex. As the solubility of the complexes is poor, only inter ligand transitions are observed, the less energetic one is connected with the formation of imine group within Schiff base. The more interesting thus are the spectra in solid state, in which, due to the technique used, the low intensity d-d transitions can be also observed. The reflectance spectra, after Kubelka-Munk transformation, are presented separately for diamagnetic (Fig.  3) and paramagnetic (Fig. 4) complexes. The presented spectra are very similar to that in solution, for paramagnetic complexes the d-d bands are better visible, as in solution these forbidden transitions have a very low intensity, compared to allowed CT ones. 
Magnetic measurements
To find the exact oxidation state of vanadium, the magnetic susceptibility measurements were performed using a magnetic Ewan's balance. The calculated magnetic moments are presented in the Experimental part. Complexes 1, 2, 4, 6 and 8 were diamagnetic, while the magnetic moment of complexes 3, 5, 7 and 9 indicate on V(IV) with d 1 configuration. The EPR spectra of complexes, were measured both at room and at liquid nitrogen temperature for solid samples and are in agreement with the magnetic susceptibility data. The EPR spectra at room temperature show g parameter equal to 1.978 (3), typical for vanadium(IV). The absence of hyperfine structure indicates on V-V interaction in condensed phase, both at room and at liquid nitrogen temperature.
Thermogravimetry
Thermal decomposition processes for complexes 3 and 9 are presented in Fig. 5 , while numerical data are collected in Table 6 . The decomposition of complex 3 starts early, the final mass loss is 90.17 %, calculated for EtOH and ligand release is 92.09, these both values fit quite well including oxidation processes and formation of V 2 O 5 as a final product. For complex 9 several, not well resolved, decomposition processes can be seen in Fig. 5 . The raft estimations gave in Table 6 show that water is released in two separated steps and then phen ligand is released. As the plateaus are not well reached (see Fig. 5 ) the mass loss can only be estimated (basing on SDTA plots). The next step is two-step decomposition of ligand L, probably, as indicated in Table 6 , first hydrazide and then in second step aldehyde part of the ligand are released. Such a stepwise decomposition of Schiff base ligand was observed earlier by us [9, 10, 26] . The total mass loss is 96.90 %, calculated 93.03 %. 
* -rest of the peaks, shown in Fig. 5 were not listed, a Δm calculated for release of hydrazide part of the ligand, b Δm calculated for release of the aldehyde from the ligand. Table 6 . The TG and SDTA data for complexes 3 and 9. Scan speed 10 o /min. is present, such a stabilization is not observed, and in 4 redox processes are less energetic.
Complex stability in solution
The admission of vanadium complexes in in vitro and in vivo studies complicates theirs solubility, stability on transfer through digestion system (with pH as low as 2.0) and transfer to the cell. Due to the almost insolubility in water of synthesized complexes, we were forced to use DMSO as a solvent in the mixture with water. DMSO is very popular in medicine as it helps in transfer of many substances through biological membranes. However, in in vitro studies, the main medium for cells is water (as solvents for all biological buffers and media). We firstly studied the stability of the complexes in pure DMSO, by measuring the UV-Vis spectra versus time. We have found, that the solutions of all 1-9 complexes are stable in DMSO. In DMSO-H 2 O (20 µl + 3ml, respectively) mixtures at native pH complexes are fairly stable and only small decomposition is observed (less than 10% of decomposition after 90 min). At pH = 2.00 complexes 5 and 7 are stable, while others undergoes slow decomposition, still over 50% of initial complex amount remains after 90 minutes. All these facts indicate, that all studied complexes are stable enough to survive the conditions present in human digestion system. The sample spectra changes for complex 6 are presented in Fig. 8 . 
Biological activity of selected complexes
All tested complexes (2, 3, 5, 7, 9-11) as well as comparative compounds (VOSO 4 , BMOV and suramin) were shown the inhibitory effect on human recombinant PTP1B at 100 μM concentration (P≤.001) as shown in Fig. 9 . All complex showed a weaker degree of inhibition both to the inorganic vanadium reference compound and to the organic vanadium complex BMOV [bis(maltolato)oxovanadium(IV)] whose pharmacological activity has been extensively studied and which has been in phase III clinical trials. The compounds 5 and 9 have been shown a significantly more potent PTP1B inhibition ability than the other tested compounds and over twice higher inhibition than suramin. The very important part in application of compounds is their cytotoxicity. The cytotoxicity of tested compounds on HepG2 hepatocytes is presented in Fig. 10 . The results were normalized to the control (cells with solvent only), wherein the intensity of fluorescence was taken as 100%. The complex 3 does not show significant cytotoxicity compared to control and to VOSO 4 or BMOV, while all other complexes possesses high cytotoxicity.
Conclusions
Nine new complexes of vanadium with ONO donating Schiff hydrazido-hydrazones are described and characterized. All complexes contain the V=O group. The bidentate co-ligands not only stabilize the V(IV) oxidation state, but also stabilize complexes in solution, even at pH 2.00. The stabilization at low pH is very important in vanadium applications as pharmaceuticals. In contrary to bidentate ligands, as in BMOV, coordination of tridentate ligand results in strong dependence of biological activity (cytotoxicity and inhibition of human PTP1B) on type of ligand used. This, together with complex stability, indicates that ONO ligand is not released during migration to the cells and the biological activity depends on ONO ligand composition and not only on presence of VO 2+ anions. Further studies are in progress. 
